2022
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Molecular Psychiatry 2022, 27: 5096-5112. PMID: 36071111, PMCID: PMC9763119, DOI: 10.1038/s41380-022-01757-7.Peer-Reviewed Original ResearchConceptsMontgomery-Åsberg Depression Rating ScaleIndividual patient-level dataRating ScalePatient-level featuresDepression Rating ScaleHamilton Rating ScalePatient-level dataPrecision medicine approachRelevant psychiatric diagnosisEligible trialsIntravenous ketamineAntidepressant medicationStudy entryKetamine infusionPrior medicationAntidepressant propertiesKetamine effectsControl armClinical moderatorsTreatment decisionsTreatment resistanceStudy-level moderatorsDepressive symptomsPersonalized prescriptionDepression severity
2020
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson S, Kitay B. Ketamine, Esketamine, and A New Generation of Antidepressants. Psychiatric Annals 2020, 50: 54-61. DOI: 10.3928/00485713-20200113-02.Peer-Reviewed Original ResearchTreatment-resistant depressionGamma-aminobutyric acid (GABA) neurotransmitter systemRapid-acting antidepressantsSAGE-217Clinical evidenceAntidepressant propertiesPostpartum depressionNeurotransmitter systemsLate-stage developmentClinical practiceDrug AdministrationUS FoodFDA approvalKetamineEsketamineAntidepressantsRegulatory approvalDepressionApprovalAllopregnanoloneBrexanoloneS-enantiomerRisk evaluationTherapyAdministration